Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.05 4.17% 1.25 21,608,942 14:08:41
Bid Price Offer Price High Price Low Price Open Price
1.20 1.30 1.40 1.225 1.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.47 -0.30 -0.11 5
Last Trade Time Trade Type Trade Size Trade Price Currency
16:31:00 O 250,000 1.35 GBX

Feedback (FDBK) Latest News (4)

More Feedback News
Feedback Takeover Rumours

Feedback (FDBK) Share Charts

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Intraday Feedback Chart

Intraday Feedback Chart

Feedback (FDBK) Discussions and Chat

Feedback Forums and Chat

Date Time Title Posts
17/10/201918:20FEEDBACK plc Medical Imaging Technology3,712
17/10/201915:21Feedback 7
01/11/201815:33****Feedback PLC****3,006
03/2/201011:50Feedback looks interesting - could easily be a ten bagger over next year396
03/9/200211:53ainsley long .........................quick shart it2

Add a New Thread

Feedback (FDBK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-17 15:31:011.35250,0003,375.00O
2019-10-17 15:30:521.35250,0003,375.00O
2019-10-17 15:30:511.35500,0006,750.00O
2019-10-17 15:30:081.20195,7192,348.63O
2019-10-17 15:09:261.2149,048593.97O
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 1.20p.
Feedback Plc has a 4 week average price of 1.03p and a 12 week average price of 0.90p.
The 1 year high share price is 2.10p while the 1 year low share price is currently 0.58p.
There are currently 373,283,250 shares in issue and the average daily traded volume is 1,471,163 shares. The market capitalisation of Feedback Plc is £4,666,040.63.
ged5: On Friday there were 12 companies that hadn't issued an RNS but rose by 10% or more. I have listed them here with the NOMAD (except DKE where it's the broker) and the approximate time of the rise ALTN VSA Capital up most of day but after 2:00 CLON Strand Hanson up from 2:00 CGNR Allenby Capital up just before 4:00 LME Cairn Financial Advisors but have Peterhouse as broker Before 10:00 AXM Cairn Financial Advisors before 10:00 Had an announcement on 25-9-19 CIP Strand Hanson Limited up over 20% just after 11:00 NET FinnCap Limited up about 10% about 1:30 Had an announcement 25-9-19 INTO No available information PHD Finncap Limited up over 10% just after 11:00 FLX Stifel Nicolaus Europe Limited, Nomad and Joint Broker up just over 10% at 9:00 DKE Peterhouse Capital Up about 10% just after 2:00 So there were other companies with more than 10% rises but no "speeding ticket" There were some when the rise was early enough to give a statement. So was the Nomad correct in making the Statement re share price? Technically they should all have done. So why FDBK? Conspiracy theories about the company or Nomad to try to suppress the SP? It just didn't make sense to me. I think this is culprit: tradinstock ‏ @TradeInStock247 Sep 27 #FDBK #IQAI mkt not getting it yet they use our techno -Texrad technology that is used by StONECHECKER of IQAI.This has just been FDA hxxp://approved.In other words Texrad has actually been FDA approved by default today! rns later or MONDAY IT IS WRONG TO MAKE MISLEADING/INCORRECT COMMENTS TO INFLUENCE THE SHARE PRICE That tweet was clearly wrong and misleading. Any comments?
ged5: Then on being questioned by Hazl I posted this:- I see that in May 2016 FDBK agreed to sell its 50% equity interest in Stone Checker Software Ltd ('Stone Checker') to Free Association Books Limited, a company connected to one of Feedback's directors, Trevor Brown, for a cash consideration of £46,000 (the "Disposal"). Then in June 2017 8,000,000 ordinary shares of £0.01 each in the capital of the Company (the Consideration Shares) to the shareholders of Stone Checker Software Limited (the Target) in connection with the acquisition by the Company of the Target (the Acquisition). I've seen elsewhere the share price was 3p. I'm not sure who held the other 50% at this time. I must admit I'm not really interested in IQAI other than: 1. How much royalties FDBK receives on any sales of Stonechecker 2. What are the circumstances where TexRAD may terminate this agreement 3. Can Stonechecker receive FDA approval before Texrad 4. If Stonechecker receives FDA approval will it improve Texrad's chance of approval? Answer to No. 2:- TexRAD Limited is entitled to terminate the Patents Licence if: (1) it is determined by an expert that the Target has without legitimate reason failed to use diligent and reasonable efforts to develop and commercially exploit the TexRAD Plug-in; (2) the Target is in material breach of the Patents Licence and such breach is not remedied, if capable of remedy, within 30 days; or (3) if the Target becomes insolvent. The Patents Licence requires the Target to pay TexRAD Limited royalty payments. Accordingly, if the Target failed to meet these payments and failed to remedy this breach within 30 days, and this was determined to be a material breach of the Patents Licence, TexRAD would be entitled to terminate the Patents Licence. Accordingly, a key risk is that the Patents Licence is terminated. Http://
lr2: Duc, they must have seen the share price rising and knowing they couldn't buy in before the year end results are announced they decided to pour iced water on the share price heat. :)
tidy 2: RNS Number : 0086OFeedback PLC27 September 2019Feedback plcStatement re share priceCambridge, 27 September 2019: Feedback plc (AIM: FDBK, "Feedback" or the "Company") notes the movement in the share price today. The Company notes the announcement earlier today by IQ-AI Ltd that Imaging Biometrics, IQ-AI's Milwaukee based subsidiary, today received notification that the FDA has cleared StoneChecker Software for marketing in the USA ("the FDA Clearance"). Stonechecker is a licensee of Feedback's TexRAD(R) software and the Directors believe that the Stonechecker Software uses TexRAD(R) . However, the Company is currently not able to evaluate what level of income, if any, will accrue as a result of the FDA Clearance. In addition, the FDA Clearance does not confer FDA clearance for TexRAD(R) and the Directors are now evaluating the implications of this as part of their ongoing strategic review.A further announcement will be made in due course.
hazl: If they are irrelevant why do you keep discussing them? The share price mostly ,has been more positive lately because we are working up to something significant. You keep talking about a few placing shares that have HAPPENED. Perhaps,those taking part in the placing,are actually interested in Bleepa and regard their shares as an investment? Whilst shares often do drift back to a placing price, these didn't ,but have continued to go up in steps,with natural drop-backs,because of the significance of Bleepa and the scenario that has developed in my opinion. Basically, I see it as fresh news driving the share price and therefore a re-rating. More important than that probably is the wider-market and what is happening there.
lr2: Megan, 1. If the full £2 million was placed why did the placing note say "The Company has received letters of subscription for, in aggregate, 57,700,000 Subscription Shares." A fully subscribed placing would have resulted in 166,666,667 Subscription Shares having been taken up on the day. Maybe they have now but they hadn't then. 2. If you were happy to subscribe at 1.5p, the question you should be asking is why couldn't the company raise £2 million at that price. The company only thought 1.2p a share was worth trying to get. Perhaps that's all they think a share is really worth at present. Not wrong either, that's exactly where the price is today. 3. If the leak wasn't planned then it was an astonishing coincidence that the "Placing and the Subscription will result in the issue of a total of 166,666,667 New Ordinary Shares, representing, in aggregate, approximately 30.87 per cent. of the Enlarged Share Capital." The Placing Price represents a true discount of approximately 31.42% to the closing mid-market price of 1.75 pence per Ordinary Share on the day before the placing was leaked. (The last day the share price didn't decline before the placing was announced.) 30.78% vs. 31.42% is close enough in my eyes to tell me that the placing was almost certainly leaked and that the share price was pushed down to the appropriate level to facilitate it. The markets knew precisely what was going on and the board didn't have the guts to pull the plug in disgust. They took the easy option and screwed their long term shareholders again. 4. If the company "were very angry about the leak" then why has the status quo remained in place? If the leak came from the board then we should have seen heads rolling. If the leak came from promoters (or their customers) then they should be sacked and replaced. As nothing has happened then I must assume that nobody gives a damn. Good luck with your new holding. I imagine you will be selling as soon as possible so you can take part in some other placing much like the vast majority of people who are about to acquire new shares.
lr2: Davydoo, re your post #2100. It's not about raising money per se, it's about the company not being able to keep the news secret and the timing of the raise (before not after Bleepa display). I've lost count of the times the share price has retreated badly prior to the release of placing news. That constant inability to keep placings secret means the company always has to issue more shares than would otherwise be the case to obtain a similar cash amount. These leaks either come from the board or from their advisors. If they come from the board then heads should roll, if they come from the advisors then they should be replaced. If they had kept things secret this time around then, on a 124 million share raise at the pre-leak share price of 1.8p the company would have raised £2.232 million. Using a post-leak price of say 1.2p (now looking doubtful) then the company raises only £1.488 million. Net loss to existing share holders of £744k. Maybe adds up to 6 further months of blissful placings free time. I sincerely hope that the board find another way of funding any supposed cash shortfall if only to stuff the shorters here who must be laughing their heads off yet again. If, as many people suspect, the shortfall is only temporary until such time as multiple Bleepa contracts roll in or TexRAD Lung (Clinical Version) is released then what the hell are the board doing giving in to the shorters in this very short time frame?
tim000: Sorry I haven't posted at all recently, but have had nothing to contribute. I still hold 2.6 mn shares so am as keen as most for FDBK to succeed. Personally, I think the FDA approval, and the opening up of the US market, remains the key trigger for a rerating of the share price. In the meantime, I guess the share will remain volatile. When I spoke to the Chairman near the end of last year, he was full of confidence that the company's technology was worth multiples of the then share price (1.5p), and I don't think anything has changed since then. Patience is the key. Finally, as has been said above, the continued buying of the two large shareholders shows that they too think the company has a great future. And they know more about its prospects than nearly anyone.
kinwah: Times article today on the NHS looking to fast-track new machine learning technologies. At least it has given the FDBK share price a boost.
hedgehog 100: From the IQAI thread: LR2 8 May '19 - 20:59 - 136 of 193 " ... Regarding Trevor Brown, I'd never bumped into him before Feedback but when I did I was disgusted at aspects of his behaviour and decided to investigate him. That was enlightening. The main thing I found at that time was him posting both here and elsewhere under two different pseudonyms and what he posted was, I believed, detrimental to Feedback in general and TexRAD in particular. Ironic really when TexRAD was, and still is, the core software component of Stone Checker. ... " LR2, As promised after your postings on the IQAI thread today, I am paying a 'return visit' ... it would be rude not to! Are you aware of the irony of your being 'so disgusted' at someone posing negative comments about a company? So disgusted apparently that you decide to do exactly the same yourself! And under two different pseudonyms (LR2 here, and Elartu on LSE). And your grudge against Trevor Brown seems to be a classic case of 'shooting the messenger for the message'. You don't like the fact that he flagged up some time ago that FDBK had the wrong strategy. Though all the evidence suggests that he was absolutely right. So if you're going to get angry against anyone, surely you should get angry with the FDBK directors who ignored his advice, rather than with TB for giving that advice? Or am I missing something? It's also deeply concerning that you apparently wish that this important information for investors in FDBK should have been suppressed. So let me set out a few home truths about FDBK. Let's make it a round ten, shall we? (Albeit they're probably obvious to many FDBK shareholders here ... how many have I heard say 'it's just not worth me selling now ...'?) - • Public question marks about the company's strategy. • A pitiful 4% sales growth (at its interim stage) after years of trying. • £738K. annualised pre-tax losses at the interim stage. • Those losses will increase with the recruitment drive etc. • Current cash likely to be below £1M., probably enough for about a year. • Little potential short term excitement expected. • No exciting growth story. • Chart in an entrenched downtrend, and generally declining trading volumes. • No recent director share buying, despite the depressed share price, and not being in a close period. • By the end of 2019 FDBK will be in fundraising countdown mode, with one due within months by then. Who would like to predict the price of FDBK's next fundraising? Current share price 0.725p, market cap. £2.71M. Don't be surprised if IQAI's sales in the current year are actually HIGHER than FDBK's. As well as its losses and current market cap. (£1.44M. at 1.2p) being LOWER. And as regards turnover growth rate ... IQAI will just blow FDBK away.
Feedback share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191018 00:26:08